Giles Wilson Acquires 68,313 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson acquired 68,313 shares of Dr. Martens stock in a transaction dated Thursday, June 25th. The shares were bought at an average price of GBX 72 per share, with a total value of £49,185.36.

Giles Wilson also recently made the following trade(s):

• On Thursday, June 11th, Giles Wilson bought 202 shares of Dr. Martens stock. The stock was bought at an average price of GBX 74 per share, with a total value of £149.48.
• On Wednesday, May 13th, Giles Wilson bought 233 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 64 per share, for a total transaction of £149.12.
• On Tuesday, April 14th, Giles Wilson purchased 232 shares of Dr. Martens stock. The shares were bought at an average price of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Stock Down 1.3%

LON:DOCS traded down GBX 0.90 during midday trading on Friday, hitting GBX 71.10. 714,890 shares of the company were exchanged, compared to its average volume of 8,611,851. Dr. Martens plc has a fifty-two week low of GBX 59.15 and a fifty-two week high of GBX 100.87. The company has a market capitalization of £680.49 million, a PE ratio of 29.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.25. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27. The company has a fifty day simple moving average of GBX 68.37 and a 200 day simple moving average of GBX 69.35.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. The company had revenue of £764.90 million during the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. As a group, equities analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Analyst Ratings Changes

DOCS has been the subject of a number of research reports. Berenberg Bank reduced their price objective on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 100 price target on shares of Dr. Martens in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.